» Articles » PMID: 22079428

Absence of Mannose-binding Lectin Prevents Hyperglycemic Cardiovascular Complications

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2011 Nov 15
PMID 22079428
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes, stress, pharmaceuticals, surgery, and physical trauma can lead to hyperglycemic conditions. A consistent relationship has been found between chronic inflammation and the cardiovascular complications of hyperglycemia. We hypothesized that cardiomyopathy and vasculopathy resulting from acute hyperglycemia are dependent on mannose-binding lectin (MBL) and lectin complement pathway activation. Hyperglycemia was induced in wild-type (WT) C57BL/6 and MBL-null mice after streptozotocin administration. Echocardiographic data and tissue samples were collected after 4, 7, or 14 days of acute hyperglycemia. Hyperglycemic WT mice demonstrated dilated cardiomyopathy with significantly increased short and long axis area measurements during systole and diastole compared to hyperglycemic MBL-null mice. The EC(50) for acetylcholine-induced relaxation of mesenteric arterioles in WT mice after 4 days of hyperglycemia demonstrated a significant loss of nitric oxide-mediated relaxation compared to normoglycemic WT or hyperglycemic MBL-null mice. Myocardial histochemistry and Western blot analysis revealed a significant influx of macrophages, altered morphology, and increased elastin and collagen deposition in hyperglycemic WT hearts compared to MBL-null hearts. Serum transforming growth factor-β1 levels were significantly lower in hyperglycemic MBL-null compared to WT mice, suggesting decreased profibrotic signaling. Together, these data suggest that MBL and the lectin complement pathway play a significant role in vascular dysfunction and cardiomyopathy after acute hyperglycemia.

Citing Articles

Circulating mannose-binding lectin in diabetic patients and risk of vascular complications: a systematic review and meta-analysis.

Sedghi M, Ranjbaran A, Forouhi M, Nejatianfar M, Azmi-Naei N, Esfahani P J Diabetes Metab Disord. 2024; 23(2):2131-2142.

PMID: 39610514 PMC: 11599526. DOI: 10.1007/s40200-024-01478-4.


Association of MBL2 gene polymorphisms and MBL levels with dilated cardiomyopathy in a Chinese Han population.

Mao Y, Wei H, Gong Y, Peng L, Chen Y BMC Med Genomics. 2024; 17(1):11.

PMID: 38167099 PMC: 10763076. DOI: 10.1186/s12920-023-01787-2.


Plasma levels of mannan-binding lectin-associated serine proteases are increased in type 1 diabetes patients with insulin resistance.

Kietsiriroje N, Scott G, Ajjan R, Broz J, Schroeder V, Campbell M Clin Exp Immunol. 2023; 215(1):58-64.

PMID: 37832142 PMC: 10776244. DOI: 10.1093/cei/uxad113.


Association of ficolin-2 (FCN2) functional polymorphisms and protein levels with rheumatic fever and rheumatic heart disease: relationship with cardiac function.

Elshamaa M, Hamza H, El Rahman N, Emam S, Elghoroury E, Farid T Arch Med Sci Atheroscler Dis. 2019; 3:e142-e155.

PMID: 30775605 PMC: 6374577. DOI: 10.5114/amsad.2018.80999.


Global Autorecognition and Activation of Complement by Mannan-Binding Lectin in a Mouse Model of Type 1 Diabetes.

Axelgaard E, Ostergaard J, Haxha S, Thiel S, Hansen T Mediators Inflamm. 2017; 2017:9403754.

PMID: 28751823 PMC: 5485322. DOI: 10.1155/2017/9403754.


References
1.
Wada K, Montalto M, Stahl G . Inhibition of complement C5 reduces local and remote organ injury after intestinal ischemia/reperfusion in the rat. Gastroenterology. 2001; 120(1):126-33. DOI: 10.1053/gast.2001.20873. View

2.
Walsh M, Shaffer L, Guikema B, Body S, Shernan S, Fox A . Fluorochrome-linked immunoassay for functional analysis of the mannose binding lectin complement pathway to the level of C3 cleavage. J Immunol Methods. 2007; 323(2):147-59. PMC: 1976379. DOI: 10.1016/j.jim.2007.04.004. View

3.
Busche M, Walsh M, McMullen M, Guikema B, Stahl G . Mannose-binding lectin plays a critical role in myocardial ischaemia and reperfusion injury in a mouse model of diabetes. Diabetologia. 2008; 51(8):1544-51. PMC: 2542900. DOI: 10.1007/s00125-008-1044-6. View

4.
Zieman S, Kass D . Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs. 2004; 64(5):459-70. DOI: 10.2165/00003495-200464050-00001. View

5.
Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G . Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med. 2005; 22(8):999-1004. DOI: 10.1111/j.1464-5491.2005.01562.x. View